A Phase 1 Trial of a Single ProHemaÂ® CB Product for Pediatric Patients With Hematologic Malignancies
This is an open-label, safety study of a single ProHema-CB product administered following myeloablative conditioning regimen in pediatric subjects with hematologic malignancies.
Hematologic Malignancies
BIOLOGICAL: Biological: ProHema-CB
Safety Profile, Primarily Assessed by Neutrophil Engraftment, To describe the safety profile of ProHema-CB after myeloablative conditioning in pediatric patients with hematologic malignancies. The safety profile will primarily be assessed by neutrophil engraftment., Neutrophil engraftment by Day 42
A maximum of 18 eligible male and female subjects (1 to 18 years old, inclusive) will be enrolled and treated in the trial at approximately 3 to 5 centers within the U.S. These 18 subjects will consist of 3 cohorts of 6 subjects each. The cohorts will be defined by age: 1 to 4 years; \> 4 to 12 years; and \> 12 to 18 years. These cohorts will be enrolled simultaneously.

All subjects will be admitted to the hospital, per institutional practice, and will receive a myeloablative conditioning regimen, after which they will receive an HLA-matched or partially matched ProHema-CB unit on study Day 0.